- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00023907
Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase II Evaluation of Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum and Paclitaxel-Resistant Ovarian or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
OBJECTIVES:
- Determine the antitumor activity of paclitaxel in patients with recurrent or persistent platinum- and paclitaxel-resistant ovarian epithelial or primary peritoneal cancer.
- Determine the nature and degree of toxicity of this drug in these patients.
OUTLINE: Patients receive paclitaxel IV over 1 hour once weekly for 4 weeks. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 19-51 patients will be accrued for this study within 6-12 months.
Typ studie
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Arizona
-
Phoenix, Arizona, Spojené státy, 85006-2726
- CCOP - Western Regional, Arizona
-
-
California
-
Los Gatos, California, Spojené státy, 95032
- Women's Cancer Center at Community Hospital of Los Gatos
-
Orange, California, Spojené státy, 92868
- Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center
-
-
Delaware
-
Newark, Delaware, Spojené státy, 19713
- CCOP - Christiana Care Health Services
-
-
Hawaii
-
Honolulu, Hawaii, Spojené státy, 96813
- MBCCOP - Hawaii
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60612
- MBCCOP - University of Illinois at Chicago
-
Chicago, Illinois, Spojené státy, 60612-3824
- Rush-Presbyterian-St. Luke's Medical Center
-
Evanston, Illinois, Spojené státy, 60201
- CCOP - Evanston
-
Springfield, Illinois, Spojené státy, 62794-9640
- Memorial Medical Center
-
Urbana, Illinois, Spojené státy, 61801
- CCOP - Carle Cancer Center
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202-5289
- Indiana University Cancer Center
-
South Bend, Indiana, Spojené státy, 46617
- Saint Joseph Regional Medical Center
-
-
Iowa
-
Iowa City, Iowa, Spojené státy, 52242-1002
- Holden Comprehensive Cancer Center at University of Iowa
-
-
Kentucky
-
Lexington, Kentucky, Spojené státy, 40536-0084
- Markey Cancer Center at University of Kentucky Chandler Medical Center
-
-
Maryland
-
Bethesda, Maryland, Spojené státy, 20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48106
- CCOP - Michigan Cancer Research Consortium
-
Grand Rapids, Michigan, Spojené státy, 49503
- CCOP - Grand Rapids
-
Kalamazoo, Michigan, Spojené státy, 49007-3731
- CCOP - Kalamazoo
-
-
Minnesota
-
Saint Louis Park, Minnesota, Spojené státy, 55416
- CCOP - Metro-Minnesota
-
-
Mississippi
-
Keesler AFB, Mississippi, Spojené státy, 39534-2576
- Keesler Medical Center - Keesler Air Force Base
-
-
Missouri
-
Columbia, Missouri, Spojené státy, 65203
- Ellis Fischel Cancer Center at University of Missouri - Columbia
-
Kansas City, Missouri, Spojené státy, 64131
- CCOP - Kansas City
-
Springfield, Missouri, Spojené státy, 65807
- CCOP - Cancer Research for the Ozarks
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68106
- CCOP - Missouri Valley Cancer Consortium
-
-
New York
-
Buffalo, New York, Spojené státy, 14263-0001
- Roswell Park Cancer Institute
-
-
North Carolina
-
Chapel Hill, North Carolina, Spojené státy, 27599-7295
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
-
Durham, North Carolina, Spojené státy, 27710
- Duke Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Spojené státy, 27157-1065
- Comprehensive Cancer Center at Wake Forest University
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45267-0526
- Charles M. Barrett Cancer Center at University Hospital
-
Cleveland, Ohio, Spojené státy, 44195
- Cleveland Clinic Taussig Cancer Center
-
Cleveland, Ohio, Spojené státy, 44106
- Ireland Cancer Center
-
Columbus, Ohio, Spojené státy, 43210-1240
- Arthur G. James Cancer Hospital - Ohio State University
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97225
- CCOP - Columbia River Oncology Program
-
-
Pennsylvania
-
Abington, Pennsylvania, Spojené státy, 19001-3788
- Abington Memorial Hospital
-
Danville, Pennsylvania, Spojené státy, 17822-2001
- CCOP - Geisinger Clinic and Medical Center
-
Hershey, Pennsylvania, Spojené státy, 17033-0850
- Penn State Cancer Institute at Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, Spojené státy, 19111
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, Spojené státy, 15213-3180
- Magee-Womens Hospital
-
-
Tennessee
-
Knoxville, Tennessee, Spojené státy, 37917
- Southeast Gynecologic Oncology Associates
-
Nashville, Tennessee, Spojené státy, 37232-2516
- Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
-
Nashville, Tennessee, Spojené státy, 37203
- Genecologic Oncology Network
-
-
Texas
-
Galveston, Texas, Spojené státy, 77555-0587
- University of Texas Medical Branch
-
Temple, Texas, Spojené státy, 76508
- CCOP - Scott and White Hospital
-
-
Wisconsin
-
Marshfield, Wisconsin, Spojené státy, 54449
- CCOP - Marshfield Clinic Research Foundation
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dítě
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
DISEASE CHARACTERISTICS:
- Histologically confirmed recurrent or persistent ovarian epithelial or primary peritoneal cancer
Measurable disease
At least 1 lesion measured in at least 1 dimension
- At least 20 mm by conventional techniques OR
- At least 10 mm by spiral CT scan
At least 1 target lesion
- Tumors within a previously irradiated field considered non-target lesions
Paclitaxel resistant
- Treatment-free interval of less than 6 months duration after treatment with prior paclitaxel OR
- Progression during prior paclitaxel-based therapy
Platinum resistant or refractory
- Treatment-free interval of less than 6 months duration after treatment with prior platinum OR
- Progression during prior platinum-based therapy
- Ineligible for higher priority GOG protocol (any active GOG phase III protocol for the same patient population)
PATIENT CHARACTERISTICS:
Age:
- Any age
Performance status:
- GOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- SGOT no greater than 2.5 times ULN
- Alkaline phosphatase no greater than 2.5 times ULN
Renal:
- Creatinine no greater than 1.5 times ULN
Other:
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
- No active infection requiring antibiotics
- No other prior invasive malignancy within the past 5 years except nonmelanoma skin cancer
- No grade 2 or greater neuropathy (sensory and motor)
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 3 weeks since prior biologic or immunologic agents for cancer
Chemotherapy:
- See Disease Characteristics
- At least 3 weeks since prior chemotherapy for cancer and recovered
- Received at least 1 but no more than 2 prior platinum-based chemotherapy regimens containing carboplatin, cisplatin, or other organoplatinum compound for primary or recurrent disease
- Initial treatment may include high-dose therapy, consolidation, or extended therapy
- Received at least 1 prior paclitaxel-based chemotherapy regimen
- No prior paclitaxel or docetaxel with a schedule of less than a 3-week interval between doses
- No additional prior cytotoxic chemotherapy for recurrent or persistent disease, including retreatment with initial chemotherapy regimens
Endocrine therapy:
- At least 1 week since prior hormonal therapy for cancer
- Concurrent hormone replacement therapy allowed
Radiotherapy:
- See Disease Characteristics
- At least 3 weeks since prior radiotherapy for cancer and recovered
- No prior radiotherapy to site(s) of measurable disease
- No prior radiotherapy to more than 25% of marrow-bearing areas
Surgery:
- At least 3 weeks since prior surgery for cancer and recovered
Other:
- At least 3 weeks since other prior therapy for cancer
- No prior anticancer treatment that would preclude study
- No concurrent amifostine or other protective reagents
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Maskování: Žádné (otevřený štítek)
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Studijní židle: Maurie Markman, MD, The Cleveland Clinic
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- CDR0000068875
- GOG-0126N
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na paclitaxel
-
Fudan UniversityNeznámýMetastatický karcinom pankreatuČína
-
Yuhong LiDokončenoSpinocelulární karcinom jícnuČína